QBIO - Q BioMed Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.0400
+0.0200 (+0.99%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close2.0200
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume69,886
Market Cap29.152M
Beta (3Y Monthly)4.62
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.92
Trade prices are not sourced from all markets
  • ACCESSWIRE11 days ago

    Demand for New Glaucoma Therapies Has Greatest Potential to Drive Value for Q BioMed's Shareholders

    NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally. The illness often remains undetected long after significant vision loss has already occurred and in the most common form, known as open-angle glaucoma, there are usually no symptoms and no pain associated with the increase in intraocular pressure that leads to optic nerve damage. A 2014 study published in Ophthalmology, the journal of the American Academy of Ophthalmology, by Y.C. Tham et al. of the Singapore Eye Research Institute projected that the number of people worldwide, aged 40 to 80 years, with glaucoma would grow from an estimated 64 million in 2013 to 76 million in 2020 and nearly 112 million people by the year 2040.

  • PR Newswire12 days ago

    Q BioMed Responds to OTC Markets Request for Clarity on Investor Awareness Activity

    NEW YORK, Feb. 7, 2019 /PRNewswire/ -- Q BioMed Inc. (QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. Expecting several corporate developments and news events, the Company's investor relations consulting firm engaged a new sub-contracted service provider on January 1, 2019, to assist in presenting the Company to a broader audience. The third-party service provider, Platinum Vlll Investment and Media LLC, has several outlets that it contracts with to provide visibility to its clients, including the Company, using its various subscriber bases.

  • PR Newswire14 days ago

    FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

    NEW YORK, Feb. 5, 2019 /PRNewswire/ -- www.FinancialBuzz.com, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (QBIO) Chairman and CEO, Denis Corin from the floor of the NASDAQ MarketSite at Times Square New York City. Mr. Corin shares with us his vision of Company's growth and why he believes 2019 and beyond are essential years for Q BioMed Inc. The interview provides unique insight into the Company's latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.

  • PR Newswire18 days ago

    Q BioMed to Present at 2019 BIO CEO & Investor Conference

    NEW YORK , Feb. 1, 2019 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today the Company's CEO Denis Corin will deliver a corporate presentation and conduct ...

  • ACCESSWIRE22 days ago

    Q BioMed Seeks Multi-billion Dollar Opportunity with New Glaucoma Treatment Candidate

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / Shares of Q BioMed Inc. (QBIO) rose on heavy volume after the company announced that a new collaboration among researchers at McMaster University, Mannin Research and the emerging biotechnology accelerator, focuses on ophthalmic drug delivery and formulation experiments for MAN-01, a first in class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery. With 70 million patients in the world, and with expectations that this will grow to 100 million in the coming years, more effective and more easily delivered glaucoma treatments are needed by ophthalmologists and patients.

  • PR Newswire25 days ago

    Q BioMed Technology Partner Mannin Research Enters Into Collaboration With McMaster University for Glaucoma Drug Candidate MAN-01

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.

  • ACCESSWIRElast month

    Imminent FDA Decision Prompts the Ignition of Q BioMed's Shares

    LOS ANGELES, CA / ACCESSWIRE / January 18, 2019 / A new report indicates that an anticipated key FDA decision is set to transform Q BioMed (QBIO) from a biotech developer to a revenue generating manufacturer in what may be record time. When Corin was asked to acknowledge the "buzz" surrounding upcoming catalysts, he stated: "A lot of the focus over the last year or so has been on the Strontium Chloride Sr-89 Injection or Metastron™ assets because its close to commercialization and I guess the first real commercial catalyst is that we're waiting for FDA approval of the manufacturing facility in South Texas.

  • PR Newswirelast month

    Q BioMed Adds Clinical Psychologist at Yale's Child Study Center, Dr. Pamela Ventola to Advisory Committee for QBM-001

    Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).

  • GlobeNewswirelast month

    Denis Corin, CEO, of Q BioMed Inc. Provides Key Update and Outlook in a New Audio Interview with SmallCapVoice.com

    SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (QBIO) (the "Company"), a commercial stage biotechnology company, announced today that a new audio interview with the Company is now available. Denis Corin, CEO of Q BioMed Inc., called in to SmallCapvoice.com to go over the innovative biotechnology firm’s business model, including a discussion about a key pending FDA catalyst which is set to help transform the company into a revenue generating biotech. Corin also dissects the importance of Q BioMed’s acquisition of Cancer Pain Drug Metastron™ from GE Healthcare and goes over the markets they aim to serve with their innovative products and formulations in various other indications.

  • PR Newswirelast month

    Q BioMed Inc Provides Shareholder Update

    Q BioMed Inc. (QBIO), a commercial stage biotechnology company provides the following update to its shareholders and interested investors. It's been proven safe and effective over many years of use.

  • PR Newswire2 months ago

    Q BioMed Announces Strategic Partnership With SRI International for Formulation and Preclinical Development of QBM-001 for Pediatric Nonverbal Disorder in Autistic Children

    Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. SRI has broad expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics.

  • PR Newswire3 months ago

    Q BioMed Inc Announces Acquisition of Cancer Pain Drug Metastron™ from GE Healthcare

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare. The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to Q BioMed to allow for as seamless a transition as possible in all markets.

  • PR Newswire4 months ago

    Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that Robert Derham, a member of the Q BioMed team and founder of CheckOrphan and architect of the world's first access program database, hosted a roundtable discussion on how companies can compliantly communicate their expanded access program and participated on a panel discussion about how to more effectively work with patients and patient organizations when executing an expanded access program. Expanded access programs are highly regulated programs that provide people with medicine that has not yet been approved on the market.

  • PR Newswire4 months ago

    Q BioMed Provides Important Update on QBM001 Developmental Drug Targeting a Non-Verbal and Minimally Verbal Patient Subset on the Autism Spectrum

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. Q BioMed continues to develop its intellectual property including its patent pending QBM-001 drug technology, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.

  • PR Newswire5 months ago

    Q Biomed Inc. Announces Entry Into Definitive Funding Agreement for $4,000,000

    Q BioMed Inc. (QBIO), is pleased to announce that it has entered into a definitive agreement with Yorkville Advisors Global ('Yorkville') for $4,000,000. Q BioMed has closed on the initial tranche of $2,000,000 and expects to close on the balance pending the filing of a registration statement with the U.S. Securities and Exchange Commission for the underlying shares. Q BioMed Inc. CEO, Denis Corin said, "We are very pleased to once again partner with Yorkville as we enter a very milestone intensive period for Q BioMed.

  • Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board
    PR Newswire5 months ago

    Q Biomed Inc. Announces Dr. Rajendra Apte Joins Advisory Board

    Distinguished Ophthalmology Specialist Brings Wealth of Experience NEW YORK , Sept. 17, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, ...

  • PR Newswire6 months ago

    Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

    NEW YORK, Aug. 20, 2018 /PRNewswire/ -- Q BioMed Inc. (QBIO) (QBIO), a commercial stage biotechnology acceleration development company, and BioNucleonics, licensor of Strontium 89 Chloride, announce submission of a supplemental regulatory filing to the FDA for the approval of a new manufacturing facility. Once cleared by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP in accordance with cGMP. Strontium Chloride Sr89 Injection USP is an FDA-approved non-opioid injectable radiopharmaceutical indicated to relieve cancer bone pain in patients with painful skeletal metastases.

  • PR Newswire7 months ago

    Q Biomed Inc. Extends its Exclusive Option Agreement With Washington University in St. Louis for a Novel Companion Biomarker for Monitoring Glaucoma and Initiates a Clinical Study

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it is extending its option agreement with Washington University in St. Louis. Under the agreement granting the exclusive right to license the technology, Q BioMed will continue to evaluate the feasibility and usability of GDF15, a novel biomarker for monitoring glaucoma, as a companion diagnostic to the MAN-01 small molecule currently being optimized for the topical treatment of glaucoma. The extension allows for more extensive evaluation to be conducted on the feasibility and usability of GDF15 as a novel biomarker for glaucoma and companion diagnostic to, Q BioMed's exclusively licensed technology, MAN-01.

  • PR Newswire8 months ago

    Q BioMed Inc. Provides Important Update on Mannin Research Tie2 Technology Platform Development

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, provides the following update on its exclusively licensed platform technology asset from Mannin Research Inc. Together with Mannin Research, the company has made significant progress on their Tie2 activating molecule - currently being optimized for a topical eye drop for the treatment of open angle glaucoma. This is a tremendous achievement and involved significant and detailed work, giving them broad coverage of the platform from an intellectual property standpoint.

  • PR Newswire9 months ago

    Q BioMed Inc Places 2nd in Company Category for Autism Speaks Walk Fundraiser

    Q BioMed Inc. (QBIO), a biotechnology acceleration company, placed second in the 'company category' at this year's Bay Area Autism Speaks Walk. The fundraiser provided Q BioMed an opportunity to connect with and better understand the autism spectrum disorder (ASD) community as the company progresses with QBM-001, which is being developed to treat pediatric developmental nonverbal disorder in toddlers with ASDs. "We gave it an all-out team effort to support the autism community, and we are happy to support Autism Speaks' efforts to raise awareness and educate, fund research, and support patients and caregivers," explained Denis Corin, CEO of Q BioMed.

  • PR Newswire11 months ago

    Q Biomed Inc. to Present at the Microcap Conference Taking Place April 9-10 at the Essex House in New York City

    NEW YORK , April 5, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer, will present at ...

  • PR Newswire11 months ago

    Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, and Bio-Nucleonics, licensor of Strontium 89 Chloride, announce submission of a regulatory filing to the FDA for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP. Strontium-89 is a non-opioid injectable radiopharmaceutical to relieve cancer bone pain in patients with painful skeletal metastases.

  • PR Newswire11 months ago

    Q BioMed Inc. to Present at 30th Annual Roth Conference, Taking Place March 11-14, 2018, in Dana Point, CA

    NEW YORK , March 9, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, announced today that Denis Corin , Chief Executive Officer will present at the ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire11 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...

  • ACCESSWIRElast year

    The Story Behind Growth: New Report Discusses CytoDyn Inc. and Q Biomed Inc. - Emerging Trends Within New Industry

    NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...